Contact

Chronic Fatigue Syndrome

Development of Peptide-Based Assays to Diagnose Chronic Fatigue Syndrome (CFS)

Chronic fatigue syndrome (CFS) is a severe disease characterized by various symptoms of immune dysfunction. CFS onset typically is associated with an infection and many patients suffer from frequently recurrent viral or bacterial infections. Epstein-Barr virus (EBV) has long been discussed as a possible cause or trigger for CFS. To date, there is no marker or single test to confirm a diagnosis of CFS.

The aim of the longtime collaboration with the team of Prof. Scheibenbogen from the Charité (Institute for Medical Immunology) is to distinguish CFS from other disease (e.g. depression) based on the disturbed immune response against EBV. The current project comprises the development of peptide-based assays for this purpose and is funded by the European Union and the program "Investition in Ihre Zukunft".

References for Chronic Fatigue Syndrome and Epstein-Barr Virus

"Multiple Sclerosis: The Elevated Antibody Response to Epstein-Barr Virus Primarily Targets, but is not Confined to, the Glycine-Alanine Repeat of Epstein-Barr Nuclear Antigen-1"
Ruprecht et al., J. Neuroimmunol. (2014) – PMID: 24798244
"Fine Specificity of the Antibody Response to Epstein-Barr Nuclear Antigen-2 and other Epstein-Barr Virus Proteins in Patients with Clinically Isolated Syndrome: A Peptide Microarray-Based Case-Control Study"
Schlemm et al., J Neuroimmunol. (2016) - PMID: 27397076
"Frequent IgG Subclass and Mannose Binding Lectin Deficiency in Patients with Chronic Fatigue Syndrome"
Guenther et al., Hum Immunol. (2015) – PMID: 26429318

 

Partners & Funding

Project partner
Prof. Scheibenbogen Institute for Medical Immunology, Charité Berlin, Germany

Funded by the European Union and the program “Investition in Ihre Zukunft”.

Funding

Partner with us

Contact: Tanja Kaan
T: +49-30-6392-7878
X: +49-30-6392-7888
E: peptide@jpt.com

Quality Assurance

All production is performed according to ISO 9001:2015 standards

Stay in touch and be the first to receive the latest news!